Literature DB >> 6620171

Effect of probenecid on the dose-response relationship of bumetanide at steady state.

H S Lau, L J Shih, D E Smith.   

Abstract

The present investigation was undertaken to clarify the determinants of the pharmacologic responses to bumetanide. The urinary excretion rate, plasma concentration and natriuretic and diuretic effects of bumetanide were evaluated under steady-state conditions in four mongrel dogs, before (Treatment I) and after (Treatment II) probenecid administration. To avoid fluid and electrolyte imbalance, urinary losses were replaced i.v. by equal volumes of lactated Ringer's solution over the time interval of the subsequent collection period. Probenecid administration caused a dramatic reduction in the renal clearance of bumetanide (5.05 +/- 1.11 for Treatment I vs. 0.716 +/- 0.285 ml/min . kg for Treatment II; P less than .002), resulting in significantly higher plasma concentrations (3-fold) and significantly lower urinary excretion rates (2.5-fold) of the diuretic. This was accompanied by concomitant reductions in bumetanide-induced diuresis and natriuresis. The results from this study demonstrate that adequate luminal levels of bumetanide are required for the pharmacodynamics of the drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6620171

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Clinical Pharmacology in Diuretic Use.

Authors:  David H Ellison
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-01       Impact factor: 8.237

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 3.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Development of acute tolerance to bumetanide: constant-rate infusion studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

5.  Development of acute tolerance to bumetanide: bolus injection studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.